In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer

Xu-ming Ji; Bing Ouyang; Heng Liu; Guo-wei Liu; Zhi-chun Wu; Hua-yun Yu; Chun-yan Wang; Zhong-xia Wang; Wen-ping Wang

doi:10.1007/s11655-011-0934-5

Your Location：

Home >

Browse articles >

In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer

Updated：2021-08-27

- In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer
- Chinese Journal of Integrative Medicine Vol. 17, Issue 12, Pages: 908-916(2011)
- Affiliations：
  
  School of Basic Medical Science, Shandong University of Traditional Chinese Medicine,Jinan,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 81072832;No.30873222) and Shandong Provincial Young and Middle-aged Scientists (No. 2008BS03010)
- DOI：10.1007/s11655-011-0934-5
  CLC：
- Published：2011，
  
  Published Online：3 December 2011，
Scan for full text
Ji, Xm., Ouyang, B., Liu, H. et al. , In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer., Chin. J. Integr. Med. 17, 908–916 (2011). https://doi.org/10.1007/s11655-011-0934-5

Xu-ming Ji, Bing Ouyang, Heng Liu, et al. In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 17(12):908-916(2011)
Ji, Xm., Ouyang, B., Liu, H. et al. , In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer., Chin. J. Integr. Med. 17, 908–916 (2011). https://doi.org/10.1007/s11655-011-0934-5 DOI：

Xu-ming Ji, Bing Ouyang, Heng Liu, et al. In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 17(12):908-916(2011) DOI： 10.1007/s11655-011-0934-5.

摘要

To observe the effect of the combination of Wenxia Changfu Formula (温下肠腑方

WCF) with cisplatin (CDDP) on inhibiting non-small cell lung cancer (NSCLC) in vitro and In Vivo and explore its mechanism from its effect on cell cycle. In vitro

WCF-containing serum was prepared and the rhubarb b1

emodin

and aconitine were detected qualitatively by high-performance liquid chromatogram (HPLC). A549 cell lines were treated with blank control (dimethyl sulfoxide)

normal serum

normal serum with CDDP (1.25

2.5

and 5.0 μg/mL

respectively)

WCF-containing serum plus different doses of CDDP (1.25

2.5

and 5.0 μg/mL

respectively). The inhibitory effect was detected by 3-(4

5)-dimethylthiazo(-zy1)-3

5-diphenylterazolium bromide (MTT). The cell cycle was detected by flow cytometry. The protein and mRNA expressions of cyclin D1

proliferating cell nuclear antigen (PCNA)

retinoblastoma (Rb)

and p16 were observed with immunofluorescence and RT-PCR

respectively. In Vivo

nude mice xenograft model was established and grouped into the control

CDDP

WCF

and combination groups. The combination’s inhibition of tumor growth and influence on the weight

spleen

and thymus gland were observed. The inhibitory rate of the combination against A549 cell lines excelled the CDDP alone significantly (P <0.05); the combination showed a synergism inhibitory effect (Q=1.19). Compared with the monotherapy

the combination increased the cell percentage in G0/G1 phase and decreased the cell percentage in S phase significantly (P <0.05); the protein and mRNA expressions of cyclin D1

PCNA

and Rb were significantly reduced; the protein and mRNA expressions of p16 were significantly enhanced. Compared with the monotherapy

the combination inhibited the tumor growth significantly In Vivo and reduced the weight of tumor (P <0.05); compared with the CDDP group

the spleen and thymus gland index of the combination group were enhanced significantly (P <0.05). The combination of WCF with CDDP significantly inhibited the A549 cell lines proliferation in vitro and the growth of the tumor In Vivo; it inhibited effectively the atrophy of the immune organ caused by chemotherapy. The combination inhibited overproliferation of A549 cell lines by arresting the G0 /G1 phase of cell cycle and affecting the protein and mRNA expressions of cell cycle-related proteins

cyclin D1

etc.

Abstract

To observe the effect of the combination of Wenxia Changfu Formula (温下肠腑方

WCF) with cisplatin (CDDP) on inhibiting non-small cell lung cancer (NSCLC) in vitro and In Vivo and explore its mechanism from its effect on cell cycle. In vitro

WCF-containing serum was prepared and the rhubarb b1

emodin

and aconitine were detected qualitatively by high-performance liquid chromatogram (HPLC). A549 cell lines were treated with blank control (dimethyl sulfoxide)

normal serum

normal serum with CDDP (1.25

2.5

and 5.0 μg/mL

respectively)

WCF-containing serum plus different doses of CDDP (1.25

2.5

and 5.0 μg/mL

respectively). The inhibitory effect was detected by 3-(4

5)-dimethylthiazo(-zy1)-3

5-diphenylterazolium bromide (MTT). The cell cycle was detected by flow cytometry. The protein and mRNA expressions of cyclin D1

proliferating cell nuclear antigen (PCNA)

retinoblastoma (Rb)

and p16 were observed with immunofluorescence and RT-PCR

respectively. In Vivo

nude mice xenograft model was established and grouped into the control

CDDP

WCF

and combination groups. The combination’s inhibition of tumor growth and influence on the weight

spleen

the combination increased the cell percentage in G0/G1 phase and decreased the cell percentage in S phase significantly (P <0.05); the protein and mRNA expressions of cyclin D1

PCNA

and Rb were significantly reduced; the protein and mRNA expressions of p16 were significantly enhanced. Compared with the monotherapy

the combination inhibited the tumor growth significantly In Vivo and reduced the weight of tumor (P <0.05); compared with the CDDP group

cyclin D1

etc.

关键词

Chinese MedicineWenxia Changfu Formulachemotherapyinhibitory effectcell cyclecell cycle-related proteinsnon-small cell lung cancer

Keywords

Chinese MedicineWenxia Changfu Formulachemotherapyinhibitory effectcell cyclecell cycle-related proteinsnon-small cell lung cancer

references

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584–594.

Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008;83:355–367.

Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997;26:14–23.

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367–1380.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med 2002;346:92–98.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2008;58:71–96.

Klastersky J, Sculier JP, Bureau G, Libert P, Ravez P, Vandermoten G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1989;7:1087–1092.

Tresure J. Herbal medicine and cancer: an introductory overview. Semin Oncol Nurs 2005;21:177–183.

Ji XM, Ouyang B. Effect of medicated serum Wenxia herbs on calcium concentration and mitochondrial membrane potential in Lovo cell. Chin J Tradit Med Sci Technol (Chin) 2006;13:176.

Oouyang B, Ji XM. Effects of medicated serum Wenxia herbs on Bcl-2, p53 expression and inducing apoptosis of Lovo cells. J Shandong Univ Tradit Chin Med (Chin) 2006;30:382–383.

Ji XM, Ouyang B, Zhang GJ, Li WH, Wang CY, Zhang YQ. Inhibitory effect of Wenxiafang on Lewis lung carcinoma in mice and influences to cell cycle. Chin J Cancer Prev Treat (Chin) 2007;14:339–341.

Ji XM, Ouyang Bing, Wang CY. Wenxia Formular restrain the multiplication of the A549 cells and the infection to the expression of PCNA, Rb and cyclin D1. Chin Arch Tradit Chin Med (Chin) 2010;28:721–723.

Ouyang B, Ji XM, Wang CY, Zhang YQ. Effects of medicated serum Wenxia Compound Prescription on erB-2, Topo-II expression and cisplatin in A549/DDP cell. J New Chin Med (Chin) 2 2008;40:101–102.

Jin ZJ. The addition in the drug combination. Acta Pharmacol Sin 1980;1:70–76.

Poot M, Zhang YZ, Krämer JA, Wells KS, Jones LJ, Hanzel DK, et al. Analysis of mitochondrial morphology and function with novel fixable fluorescent stains. Histochem Cytochem 1996;44:1363–1372.

Lau WK, Yeung CW, Lui PW, Cheung LH, Poon NT, Yung KK. Different trends in modulation of NMDARl and NMDAR2B gene expression in cultured cortical and hippocanipal neurons after lead exposure. Brain Res 2002;932:10–24.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A, et al. Paclitaxelcarboplatin alone or with Bevacizumab in non-small cell lung cancer. N Eng J Med 2006;355:2542–2550.

Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and In Vivo. J Exp Clin Cancer Res 2010;29:87–98.

Ji XM, OY B, Li WH. Effect of Wenxia herbs to immune function and restraining on tumor growth. Inf Tradit Chin Med (Chin) 2003;20:48–49.

Xia QS, Sun RY, Xiu RJ. Progress of research on molecular mechanism in antitumor effect of emodine. Chin J Integr Tradit West Med (Chin) 2009;29:85–88.

Dong LF, Zhang YJ, Liu JS, Song SX, Hou J, Lu ZJ. Anti-tumor effect of monkshood poly-saccharide with adriamycin long circulating temperature sensitive liposome and its mechanism. Chin J Cell Mol Immunol (Chin) 2006;22:458–462.

Wu FL, Shi XM, Qian H, Shan FP. The latest development of the studies on antitumor mechanism of Ginseng polysaccharides. Northwest Pharm J (Chin) 2010;25:390–391.

Cao W, Li XQ, Hou Y, Fan HT, Zhang XN, Mei QB. Structural analysis and anti-tumor activity In Vivo of polysaccharide APS-2a from Angelica sinensis. J Chin Med Mater (Chin) 2008;31:261–266.

Marx J. Researchers find new role for cell cycle proteins. Science 1994;263:1093.

Udhayakumar G, Jayanthi V, Devaraj N, Devaraj H. Interaction of MUC1 with beta-catenin modulates the Wnt target gene cyclin D1 in H. pylori-induced gastric cancer. Mol Carcinog 2007;46:807–817.

Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998;16:311–320.

Gibson SL, Dai CY, Lee HW, DePiho RA, Gee MS, Lee WM, et al. Inhibition of colon tumor progression and angiogenesis by the ink4a/Arf locus. Cancer Res 2003;63:742–746.

Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M, et al. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNAmediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 2006;95:185–194.

Lukas J, Aagaard L, Strauss M, Bartek J. Oncogenic aberrations of p16 INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995;55:4818–4823.

Zhao X, Song T, He Z, Tang L, Zhu Y. A novel role of cyclin D1 and p16 in clinical pathology and prognosis of childhood medulloblastoma. Med Oncol 2010;27:985–991.

Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003;129:199–221.

Koundrioukoff S, Jonsson ZO, Hasan S, de Jong RN, van der Vliet PC, Hottiger MO, et al. A direct interaction between proliferating cell nuclear antigen (PCNA) and Cdk2 targets PCNA-interacting proteins for phosphorylation. J Biol Chem 2000;275:22882–22887.

Cayrol C, Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 1998;17:2437–2444.

FULL TEXT LINK

More>

Views

800

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine

Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

Yiqi Zhuyu Decoction (益气逐瘀汤) Combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer

Related Author

No data

Related Institution

Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Department of Oncology, The East Campus of Dongzhimen Hospital, Beijing University of Chinese Medicine

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute

Department of Traditional Chinese Medicine, Chinese People’s Liberation Army General Hospital

Department of Radiology, Chinese People’s Liberation Army General Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰